Matching slides 6,793
Current window 5,371-5,400
Pages 227
Rows per page 30
Framework: Fraud Exposureclear collectionreset all

Framework

5,371-5,400 of 6,793

filter-aware
172
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
174
The slide uses anecdotal evidence from Facebook groups to argue against the efficacy of a treatment by highlighting inconsistencies in user reports.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
175
The slide presents a skeptical analysis of patient/parent testimonials to undermine the perceived efficacy of a drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
178
The slide uses direct quotes from Facebook group members to undermine the perceived efficacy and novelty of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
183
The slide uses a process diagram to illustrate the clinical trial flow, highlighting the transition from the failed C601 trial to the C602 withdrawal study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
184
The slide uses an excerpt from an FDA label to critique the clinical trial evidence supporting a drug's efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
185
The slide uses a red box to highlight the specific data points (weeks 12-16 of the withdrawal period) that the author claims are the basis for the company's efficacy argument.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
186
The slide uses a Q&A format to present evidence of potential trial manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
187
The slide uses a Q&A format to highlight potential data manipulation or questionable internal confidence in clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
188
The slide uses a 'quote-highlight' structure to emphasize specific allegations of misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
190
The slide uses a 'show, don't tell' approach by presenting the actual questionnaire items to demonstrate their inherent subjectivity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
191
The slide uses direct quotes from investigators to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
192
The slide uses a Q&A format to present expert testimony regarding trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
193
The slide serves as a summary of deeper investigative findings regarding clinical trial data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
194
Focuses on trial design bias and potential data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
196
Includes chemical structures of Diazoxide and Choline to illustrate the 'salt' formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
197
Includes screenshots of FDA Orange Book data and the front page of US Patent 7,572,789.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
199
The slide uses a red arrow to point from the summary list to the specific boxed text in the FDA label excerpt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
201
The slide uses a 'before-after' or 'comparison' logic to undermine the pricing power of the target company (Vykat) by highlighting readily available, cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
204
The slide uses a forensic approach to discredit clinical data, specifically targeting the validity of a poster presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
217
Uses expert quotes to debunk the necessity of the company's proprietary drug formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
225
The slide uses direct quotes from an expert consultation to undermine the credibility of the drug's approval and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
226
The slide uses direct quotes from an ex-employee to build a case of corporate misconduct regarding clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
228
The slide uses a Q&A transcript format to highlight the alleged suppression of negative clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit